Low Pretreatment Total Testosterone (< 3 Ng/mL) Predicts Extraprostatic Disease in Prostatectomy Specimens from Patients with Preoperative Localized Prostate Cancer
Authors
Affiliations
Objective: • To investigate the relationship between pretreatment testosterone levels and pathological specimen characteristics, by prospectively examining serum androgen concentrations in a well-studied cohort of patients who underwent radical prostatectomy (RP) for localized prostate cancer.
Patients And Methods: • A total of 107 patients with clinically localized prostate cancer had an assay of total testosterone before laparoscopic RP at our institution. • The results were classified into two groups based on the total serum testosterone: group1, < 3 ng/mL; group 2, ≥ 3 ng/mL. • Student's t-test was used to compare continuous variables, and Fisher's exact test or the chi-squared test was used to compare categorical variables. • Survival curves were established using the Kaplan-Meier method and compared using the log-rank test. In all tests, P < 0.05 was considered to indicate statistical significance.
Results: • All patients had localized prostate cancer based on digital rectal examination (DRE) and preoperative magnetic resonance imaging (MRI). Groups 1 and 2 were similar in terms of age, body mass index, preoperative co-morbidities (cardiovascular and diabetes mellitus), clinical stage of prostate cancer and preoperative PSA levels. • In pathological specimens, low total testosterone (< 3 ng/mL) was an independent risk factor for high Gleason score (> 7) and for locally advanced pathological stage (pT3 and pT4). • Higher preoperative testosterone correlated with disease confined to the gland. • There was no association between serum testosterone levels and surgical margin status, on the one hand, and biochemical recurrence on the other.
Conclusion: • Low serum testosterone appears to be predictive of aggressive disease (Gleason score >7 and extraprostatic disease, pathological stage > pT2) in patients who underwent RP for localized prostate cancer.
Porcaro A, Panunzio A, Bianchi A, Cerrato C, Gallina S, Serafin E Ther Adv Urol. 2023; 15:17562872231154150.
PMID: 36846295 PMC: 9950604. DOI: 10.1177/17562872231154150.
Hypogonadism and urologic surgeries: a narrative review.
Fendereski K, Ghaed M, Calvert J, Hotaling J Transl Androl Urol. 2022; 11(7):1045-1062.
PMID: 35958902 PMC: 9360521. DOI: 10.21037/tau-22-308.
Ferro M, Lucarelli G, Buonerba C, Terracciano D, Boccia G, Cerullo G Ther Adv Urol. 2022; 13:17562872211026404.
PMID: 35173812 PMC: 8842148. DOI: 10.1177/17562872211026404.
Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review.
Manceau C, Fromont G, Beauval J, Barret E, Brureau L, Crehange G Cancers (Basel). 2021; 13(17).
PMID: 34503059 PMC: 8428218. DOI: 10.3390/cancers13174251.
Kourbanhoussen K, Joncas F, Wallis C, Hovington H, Dagenais F, Fradet Y Asian J Androl. 2021; 24(1):21-25.
PMID: 34259197 PMC: 8788605. DOI: 10.4103/aja.aja_58_21.